Mindpeak and Sagis Diagnostics Launch AI Study on Nail Mycosis Detection

Mindpeak GmbH, a leader in AI-driven pathology solutions, has announced a collaboration with Sagis DX to conduct a pioneering study evaluating the effectiveness of its new Onycomycosis AI algorithm for detecting nail mycosis.

The Mindpeak Onychomycosis AI algorithm represents a groundbreaking advancement in detecting onychomycosis in PAS-stained whole slide images, highlighting AI’s transformative potential in pathology.

This innovative technology automates the detection of hyphae across multiple slides, effectively pinpointing target structures that may be sparse in whole-slide images, thus reducing the risk of missed diagnoses.

“We’re excited to collaborate with Sagis Diagnostics on this study,” said Felix Faber, CEO of Mindpeak. “This research will demonstrate the capabilities of our Onychomycosis AI while showcasing its potential to streamline workflows, save time, and enhance patient care through more accurate diagnoses.”

About Mindpeak

Founded in 2018, Mindpeak is a leader in AI-driven digital pathology solutions. The company develops advanced algorithms that assist pathologists in routine diagnostics, focusing on automating tissue analysis for quicker and more accurate results. Mindpeak’s platform aims to boost productivity and diagnostic confidence in clinical labs, ultimately improving patient outcomes in cancer care.

About Sagis Diagnostics

Sagis Diagnostics is a physician-led pathology group supported by a CLIA and CAP-accredited histology laboratory. With board-certified and subspecialty-trained pathologists readily available, we provide top-quality services to physicians, surgery centers, and hospitals. Our commitment to quality and excellence is rooted in our expertise and the latest diagnostic tools, ensuring accurate and prompt diagnoses tailored to the needs of our referring physicians. As a patient-centric facility, we aim to deliver the best possible medical care.

Source link

Newsletter Updates

Enter your email address below and subscribe to our newsletter